

# WaveSense Appoints New VP of Business Development

November 16, 2015

**IRVINE, Calif., Nov. 16, 2015** – WaveSense, Inc. ([www.wavesense.com](http://www.wavesense.com)) the leader in targeted cell isolation and enrichment from liquid biopsies, announced today that Chris Williams has joined the firm as Vice President of Business Development. Chris comes to WaveSense with more than 25 years of experience in both pharmaceutical and diagnostics industries. Chris' past experience includes roles at Millennium Pharmaceuticals, PerkinElmer and most recently SkylineDx. In his role he will work with industry leaders to expand the current WaveSense product portfolio, establish key relationships with opinion leaders, and work closely with sales and marketing to drive sales and establish the company brand.

Chris joins WaveSense to provide and build upon recent successes in providing cell isolation and enrichment technology to a growing number of the top cancer centers, medical institutions and reference laboratories. Chris commented "I look forward to working with the great people at WaveSense to provide the best possible products for cell isolation and enrichment to the diagnostic industry."

Bill Curtis, Chief Executive Officer, said "Chris' wealth of experience and industry knowledge has already made him a key addition to the WaveSense family. His appointment underscores our commitment to being the leading company in our industry. Our new innovations and the increasing demand from our customers led us to look for an addition to our team who will fit in with our ethos of innovation and exceptional service. It is very fortunate that we were able to find someone of Chris' caliber to fulfill this role."

## About WaveSense

WaveSense, based in Irvine, CA ([www.wavesense.com](http://www.wavesense.com)) is the leader in targeted cell isolation and enrichment from liquid biopsies. WaveSense's In Vitro diagnostic (IVD) products provide the most sensitive targeted cell enrichment solution, requiring only a small specimen to deliver the maximum number of pure target cells while simultaneously eliminating background cells. Without the need for expensive capital equipment, WaveSense technology enables enhanced patient diagnostic and management outcomes by optimizing the results of downstream diagnostic modalities including IHC, FISH, PCR, SNP, Gene Expression and NGS. The WaveSense platform fulfills the need to improve workflow, test sensitivity and test results while increasing revenue and reducing operational costs and complexity. WaveSense manufactures the only IVD products for paramagnetic coupled antibody targeted cell enrichment.